Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics


Nabriva Therapeutics plc - Ordinary Shares (NBRV): $2.19

-0.06 (-2.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NBRV Stock Summary

  • With a year-over-year growth in debt of -22.86%, NABRIVA THERAPEUTICS PLC's debt growth rate surpasses just 13.41% of about US stocks.
  • As for revenue growth, note that NBRV's revenue has grown 61.24% over the past 12 months; that beats the revenue growth of 85.97% of US companies in our set.
  • In terms of volatility of its share price, NBRV is more volatile than 99.45% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NABRIVA THERAPEUTICS PLC are WTT, IRIX, CFMS, RWLK, and ISO.
  • NBRV's SEC filings can be seen here. And to visit NABRIVA THERAPEUTICS PLC's official web site, go to www.nabriva.com.

NBRV Valuation Summary

  • In comparison to the median Healthcare stock, NBRV's price/earnings ratio is 106.03% lower, now standing at -1.4.
  • Over the past 88 months, NBRV's price/sales ratio has gone down 130.1.

Below are key valuation metrics over time for NBRV.

Stock Date P/S P/B P/E EV/EBIT
NBRV 2022-11-25 1.9 2.6 -1.4 -1.3
NBRV 2022-11-23 1.9 2.6 -1.4 -1.3
NBRV 2022-11-22 1.9 2.6 -1.4 -1.3
NBRV 2022-11-21 1.8 2.5 -1.4 -1.2
NBRV 2022-11-18 1.9 2.7 -1.4 -1.3
NBRV 2022-11-17 1.9 2.7 -1.4 -1.3

NBRV Growth Metrics

    The 3 year revenue growth rate now stands at 802.99%.
  • The year over year cash and equivalents growth rate now stands at -38.28%.
  • Its 5 year price growth rate is now at -93.24%.
NBRV's revenue has moved up $21,102,000 over the prior 15 months.

The table below shows NBRV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 35.625 -41.204 -47.47
2022-06-30 35.334 -48.266 -46.608
2022-03-31 34.386 -53.801 -47.288
2021-12-31 28.895 -59.557 -49.45
2021-09-30 22.094 -66.803 -54.22
2021-06-30 14.523 -66.159 -56.519

NBRV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBRV has a Quality Grade of D, ranking ahead of 14.14% of graded US stocks.
  • NBRV's asset turnover comes in at 0.2 -- ranking 199th of 681 Pharmaceutical Products stocks.
  • TECH, PRTA, and RYTM are the stocks whose asset turnover ratios are most correlated with NBRV.

The table below shows NBRV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.720 -4.035
2021-03-31 0.104 0.879 -5.458
2020-12-31 0.091 0.848 -7.042
2020-09-30 0.045 0.843 -4.960
2020-06-30 0.118 0.948 -3.969
2020-03-31 0.111 0.991 -3.268

NBRV Price Target

For more insight on analysts targets of NBRV, see our NBRV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.68 Average Broker Recommendation 1.83 (Hold)

NBRV Stock Price Chart Interactive Chart >

Price chart for NBRV

NBRV Price/Volume Stats

Current price $2.19 52-week high $18.75
Prev. close $2.25 52-week low $1.81
Day low $2.11 Volume 19,000
Day high $2.22 Avg. volume 72,799
50-day MA $2.32 Dividend yield N/A
200-day MA $5.63 Market Cap 67.10M

Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio


Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.


NBRV Latest News Stream


Event/Time News Detail
Loading, please wait...

NBRV Latest Social Stream


Loading social stream, please wait...

View Full NBRV Social Stream

Latest NBRV News From Around the Web

Below are the latest news stories about NABRIVA THERAPEUTICS PLC that investors may wish to consider to help them evaluate NBRV as an investment opportunity.

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

Yahoo | November 29, 2022

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

The Phase 1 study is testing the safety of oral and intravenous versions of lefamulin, the active ingredient in Xenleta, in adult patients with the condition.

Yahoo | November 28, 2022

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia. Nabriva plans to share more details from the open-label CF study in the first half of next year. The company's stock has tumbled 85.5% this year, while the broader S&P 500 is down 15.5%.

Yahoo | November 28, 2022

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that

Yahoo | November 28, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nabriva (NBRV) and Venus Concept (VERO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nabriva (NBRV – Research Report) and Venus Concept (VERO – Research Report). Nabriva (NBRV) H.C. Wainwright analyst Ed Arce maintained a Hold rating on Nabriva today. The company's shares closed last Thursday at $2.18, close to its 52-week low of $2.04. According to TipRanks.

Howard Kim on TipRanks | November 11, 2022

Read More 'NBRV' Stories Here

NBRV Price Returns

1-mo -8.75%
3-mo -46.42%
6-mo -56.66%
1-year -88.13%
3-year -99.55%
5-year -99.86%
YTD -85.37%
2021 -75.25%
2020 -81.67%
2019 -9.59%
2018 -75.59%
2017 0.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8001 seconds.